News Search

32 results Number of Results per Page
  1. A matter of life and death

    Date:
    Category: Partner News

    There is clearly mutual respect – and a good deal of excitement – at the launch of the new Roche Chair “Driving patient access to innovative medicines”. After all, it’s not every day that we get the chance to work on matters relating to life and death, but that is absolutely the case in this new partnership with Roche, the multinational pharmaceutical company with headquarters in Switzerland. Richard Erwin, Managing Director at Roche Belgium since 2013, explains the attraction.

  2. Belgian healthcare in need of change and improvement

    Date:
    Category: Press Releases

    Healthcare is on the brink of a revolution – or should we say an evolution? A recent white paper by the Vlerick Healthcare Management Centre at Vlerick Business School has identified four trends that are set to fundamentally change the healthcare sector, allowing for more efficiency. However, investments remain a must.

  3. Taking a look at the neighbours: what Italy can teach Belgium about healthcare

    Date:
    Category: Research News

    During each three-year term of office, MINOZ – the research centre for operational management in hospitals – organises a study trip for its members. In September, Professor Brecht Cardoen, Professor Paul Gemmel and researcher Rein Robberecht paid a visit to Milan, together with 30 participants from a total of 12 Belgian hospitals. Not only did they visit innovative hospitals, but the group also got to see how Italy tackles healthcare in general. What are the basic principles? How is it financed? Is it a competitive landscape? It turned out to be a very instructive trip.

  4. The future of M&A in the pharmaceutical industry: promoting or stifling innovation?

    Date:
    Category: Opinions

    In the research-intensive pharmaceutical industry, two rationales for M&A prevail. First, deals may be intended to provide access to target companies’ markets or innovative treatments R&D programs and, second, economies of scale could boost cost-efficiency. Both rationales lead to increased valuation of the merged company. The $119 billion takeover approach by Pfizer, the largest drug maker in the world, was resisted by AstraZeneca, another pharmaceutical giant and crown jewel of the UK-based life sciences industry at an offer representing a 45% premium over its share price before Pfizer made its move public. What went wrong and do we see a fundamental trend towards more or maybe different M&A activity in the pharmaceutical industry?

  5. Solutions driving change

    Date:
    Category: Partner News

    MSD Belgium recently entered into a Knowledge Partnership with Vlerick. The focus is on MSD’s membership of MINOZ, our research platform for hospital operations management, which brings together our researchers, representatives from hospitals, and healthcare industry partners. MSD has been a corporate partner and member of MINOZ for some years now. Jan Vertriest, Business Unit Director Immunology at MSD, explains why they wanted to continue their collaboration with us.

  6. Launch of the Vlerick Healthcare Management Centre

    Date:
    Category: Research News

    Healthcare is facing severe turmoil: patients are becoming more proactive in their treatment, while budgets are getting tighter. This is what prompted us to involve all the players within the healthcare system. The Vlerick Healthcare Management Centre is due to be launched later this year.

  7. Free trade in medicines: a fixed price for the whole of Europe?

    Date:
    Category: Opinions

    Medicines are certainly not a trivial product. They have to be approved, include an information leaflet and are exclusively available via the pharmacy, mostly by prescription only. They are also monitored in terms of both their efficacy and their safety. In one particular aspect, they are regarded as a trivial product: they are subject to the principle of free circulation in the European Union, as part of the single market. They can be imported and exported freely. The aim of free trade is that European consumers have access to all products that are available somewhere in Europe and that price differences are eliminated as a result of importing and exporting. That is a very noble objective, but with medicines it leads to shortages.

  8. Access to expensive medicines: just for those who can afford it?

    Date:
    Category: Opinions

    Naturally, patients in India and developing countries should have affordable access to medicines. It would be wrong to say that patents prevent such access and that the Indian policy of infringing patents is necessary to ensure it. The innovative pharmaceutical sector evolved a long time ago towards innovative models of co-operation and has accepted its responsibility in an increasing number of developing countries, and in consultation with policymakers and NGOs.

  9. The price of your health: is our healthcare in danger?

    Date:
    Category: Corporate News

    Will every patient need a global medical file? Can an extra 250 million euro be made available for prevention? And when will there be a radical overhaul of hospital financing? These are just a few of the pressing questions that will be addressed during the book launch for “De prijs van uw gezondheid” (“The price of your health”) by Lieven Annemans at the Brussels campus of Vlerick Business School on 26 February. Afterwards, there will be a debate featuring prominent figures from the health sector.

  10. How good is your supply chain?

    Date:
    Category: Research News

    In partnership with Groenewout and the European Logistics Association Vlerick Business School is planning an in-depth benchmark survey on supply chains in the healthcare industry. On senior management level there is a growing awareness about the importance of supply chain management. Well implemented supply chain strategies are necessary in order to make the overall company more successful. Kristof Stouthuysen, professor of Accounting, is in charge of the survey: “An agile supply chain is a competitive advantage, but in reality the majority of the supply chain structures of healthcare companies can't react flexible enough to meet the changed needs of their customer base.”

32 results Number of Results per Page

Accreditations
& Rankings

Equis Association of MBAs AACSB Financial Times